Inicio>>Signaling Pathways>> Chromatin/Epigenetics>> Epigenetic Reader Domain>>NI-42

NI-42

Catalog No.GC36734

NI-42 (compuesto 13-d), una sonda quÍmica estructuralmente ortogonal para los BRPF, es un potente inhibidor sesgado del BRD de los BRPF (IC50 de BRPF1/2/3=7,9/48/260 nM; Kds de BRPF1 /2/3=40/210/940 nM) con excelente selectividad sobre proteÍnas BRD que no son de clase IV.

Products are for research use only. Not for human use. We do not sell to patients.

NI-42 Chemical Structure

Cas No.: 1884640-99-6

Tamaño Precio Disponibilidad Cantidad
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NI-42 (compound 13-d), a structurally orthogonal chemical probe for the BRPFs, is a biased, potent inhibitor of the BRD of the BRPFs (IC50s of BRPF1/2/3=7.9/48/260 nM; Kds of BRPF1/2/3=40/210/940 nM) with excellent selectivity over nonclass IV BRD proteins[1]. BRPF1|7.9 nM (IC50)|BRPF2|48 nM (IC50)|BRPF3|260 nM (IC50)|BRPF1|40 nM (Kd)|BRPF2|210 nM (Kd)|BRPF3|940 nM (Kd)|BRD4 (BD1)|4500 nM (IC50)|BRD7|82 nM (IC50)|BRD9|310 nM (IC50)|BRD9|1130 nM (Kd)

NI-42 shows IC50s of 82, 310, and 4500 nM for BRD7, BRD9, and BRD4 (BD1), respectively, and has a Kd of 1130 nM for BRD9[1].

[1]. Igoe N, et al. Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies. J Med Chem. 2017 Jan 26;60(2):668-680.

Reseñas

Review for NI-42

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NI-42

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.